DATA-INSIGHT Study Tracking Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion Using German Health Data from 2009 to 2024

What this Trial Is About

Researchers are analyzing health data from Germany collected between 2009 and 2024 to understand how common certain eye diseases are and how their occurrence has changed over time. The diseases studied include neovascular age-related macular degeneration nAMD, diabetic macular edema DME, and retinal vein occlusion RVO. The study aims to compare data from two large health datasets, FDZ and FDGP, and to explore how factors such as age, other health issues, and medications influence these diseases. The study observes groups of people diagnosed with nAMD, DME, or RVO and examines how many receive treatment with anti-VEGF medications, which are used to slow or prevent vision loss. This is an observational study, meaning it looks at existing health records and treatment patterns without assigning any new treatments. Participants are grouped into cohorts based on their diagnosis to compare disease patterns and treatment use. Participants health data will be reviewed to measure how often new cases occur incidence and how many people have these eye diseases at a given time prevalence in Germany. Researchers will also analyze treatment rates with anti-VEGF drugs and consider demographic and health factors affecting these diseases. The study is sponsored by Bayer and aims to provide a clearer picture of eye disease impact and management over 15 years.

DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.